FDA green-lights Asklepion's Cholbam; Pfizer's Australian court fight over Lipitor discounting isn't over yet;

@FiercePharma: Sinovac close to China marketing approval for hand, foot and mouth vaccine. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Malaysia's CCM Duopharma Biotech ready to compete with the big boys, buying 6 plants from parent. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Imbruvica cocktail stalls CLL in new trial, raising hopes for bigger market. Article | Follow @CarlyHFierce

> The FDA approved Cholbam, a new drug from Baltimore-based Asklepion Pharmaceuticals, to treat bile acid and peroxisomal disorders in kids and adults. Release

> Australia's expert body that recommends drugs for subsidy has hit back at a pharmaceutical industry push to fast-track listings for new cancer medicines. Report

> Illinois drugmaker Akorn ($AKRX) has asked Alabama officials to return any Akorn-made drugs the state may be planning to use in executions by lethal injection. Report

> Pfizer's ($PFE) court fight over Lipitor discounting in Australia isn't over yet; the country's consumer watchdog says it will appeal a federal judge's decision that the company hadn't engaged in anticompetitive conduct. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Mayo Clinic finds a common MRI contrast agent is deposited in the brain. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Tablets, apps being deployed to improve customer service in the ICU. Article | Follow @VarunSaxena2

@EmilyWFierce: $MDT and the University of Minnesota are studying hibernating bears to gain insight into treating heart disease. More | Follow @EmilyWFierce

> Olympus faces more legal pushback over endoscopes linked to UCLA superbug outbreak. Article

> Vivo Capital doubles down to close $750M U.S.-China healthcare fund. Story

> Boston Scientific implantable defibrillator gets FDA green light. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Struggling GlaxoSmithKline warns of 150 R&D job cuts in Philadelphia. News | Follow @FierceBiotech

@JohnCFierce: Pfizer joins a powerhouse syndicate backing $43M round for Nimbus. News | Follow @JohnCFierce

@DamianFierce: Dear Twitter, it is my great honor to introduce FierceMadness, the 2015 Drug Name Tournament. Check it out | Follow @DamianFierce

> Retrophin bags rare disease approval, FDA voucher in $75M deal. News

> Nordic Nanovector upscales IPO as demand tops expectations. More

> Deep dive into Actelion's Uptravi data calms investors as FDA decision date nears. Story

> Nektar looks for the positive in a failed PhIII breast cancer study. Report

Biotech Research News

> Research group uses nanoparticles to deliver antibiotic. Item

> Fast-spreading CRISPR tech inspires new preclinical work on blood cancers. More

> Academic team assembles a 'homegrown' immunotoxin for blood cancers. Story

> Blood pressure drug looks promising in preventing myelin loss in MS. Article

> Rockefeller U team touts a potential psoriasis 'cure' from Boehringer. Report

Diagnostics News

> Metabolon rides on last year's success with $5M in extended financing. Story

> Illumina hits U.K. company with prenatal test patent suit. Article

> Myriad extends collaboration with BioMarin for cancer companion Dx. Item

> Invitae to focus on adding genetic tests, securing reimbursement in 2015. Report

> 23andMe launches new therapeutics group with biotech vet taking the reins. More

Pharma Marketing News

> Worried about quality at home, Chinese consumers stock up on 'Made in Japan' drugs. Item

> Judge tosses Xolair kickback suit against Novartis, Genentech. Report

> Pernix looks for a sales trifecta from 100 new Zohydro reps. Story

> Mayo docs join the revolt against rising cancer drug prices. News

> It had to happen: Apple Watch gets a drug-adherence app. More

And Finally... Aspirin may increase the risk of colorectal cancer in people with certain genetic variants, new research shows. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.